 Michael Aubrey
Concepts (140)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA-DRB1 Chains | 4 | 2016 | 98 | 0.670 |
Why?
| | Epitopes | 4 | 2016 | 438 | 0.580 |
Why?
| | HLA Antigens | 4 | 2020 | 223 | 0.430 |
Why?
| | Vimentin | 2 | 2016 | 57 | 0.420 |
Why?
| | Transplantation, Haploidentical | 2 | 2022 | 7 | 0.390 |
Why?
| | Peptides, Cyclic | 2 | 2016 | 262 | 0.370 |
Why?
| | Arthritis, Rheumatoid | 3 | 2016 | 1002 | 0.370 |
Why?
| | Graft vs Host Disease | 2 | 2023 | 212 | 0.350 |
Why?
| | Genetic Predisposition to Disease | 5 | 2016 | 2125 | 0.280 |
Why?
| | HLA-B Antigens | 2 | 2022 | 56 | 0.270 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 10 | 0.220 |
Why?
| | Alleles | 5 | 2019 | 794 | 0.220 |
Why?
| | HLA-C Antigens | 1 | 2022 | 33 | 0.200 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2022 | 72 | 0.200 |
Why?
| | Receptors, KIR | 2 | 2022 | 92 | 0.190 |
Why?
| | Transplantation Conditioning | 2 | 2020 | 150 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 863 | 0.170 |
Why?
| | Tacrolimus | 1 | 2020 | 143 | 0.170 |
Why?
| | Islets of Langerhans | 3 | 1994 | 729 | 0.170 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2019 | 16 | 0.160 |
Why?
| | Pregnancy Complications | 1 | 2023 | 430 | 0.160 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 19 | 0.150 |
Why?
| | Donor Selection | 1 | 2018 | 73 | 0.140 |
Why?
| | Graft Rejection | 1 | 2020 | 533 | 0.140 |
Why?
| | Insulin | 3 | 1994 | 2082 | 0.130 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 395 | 0.130 |
Why?
| | Tissue Donors | 1 | 2018 | 331 | 0.130 |
Why?
| | HLA-DR Antigens | 2 | 2020 | 221 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 1994 | 795 | 0.120 |
Why?
| | Peptides | 2 | 2016 | 864 | 0.110 |
Why?
| | Cyclophosphamide | 2 | 2022 | 218 | 0.090 |
Why?
| | International Cooperation | 1 | 2011 | 174 | 0.090 |
Why?
| | Cell Division | 1 | 1992 | 759 | 0.090 |
Why?
| | Algorithms | 1 | 2018 | 1490 | 0.090 |
Why?
| | Protein Binding | 2 | 2016 | 1917 | 0.090 |
Why?
| | Histocompatibility Testing | 2 | 2020 | 115 | 0.090 |
Why?
| | Gene Frequency | 3 | 2019 | 485 | 0.080 |
Why?
| | Immunoglobulin E | 1 | 2010 | 328 | 0.080 |
Why?
| | Arachis | 1 | 2010 | 147 | 0.080 |
Why?
| | Amino Acids | 1 | 2011 | 454 | 0.080 |
Why?
| | Humans | 20 | 2023 | 115587 | 0.070 |
Why?
| | Mycobacterium Infections | 1 | 1987 | 61 | 0.070 |
Why?
| | Peanut Hypersensitivity | 1 | 2010 | 199 | 0.070 |
Why?
| | Immunoglobulin G | 1 | 2010 | 781 | 0.070 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2022 | 353 | 0.070 |
Why?
| | Cricetinae | 3 | 1994 | 260 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2011 | 3022 | 0.060 |
Why?
| | Haplotypes | 3 | 2014 | 457 | 0.060 |
Why?
| | Genotype | 2 | 2022 | 1786 | 0.060 |
Why?
| | HLA-A Antigens | 1 | 2022 | 50 | 0.050 |
Why?
| | Histocompatibility Antigens | 1 | 2022 | 100 | 0.050 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2014 | 3254 | 0.050 |
Why?
| | Cell Line | 3 | 2016 | 2651 | 0.050 |
Why?
| | Interleukin-2 | 2 | 2000 | 417 | 0.050 |
Why?
| | Catechols | 2 | 2000 | 14 | 0.050 |
Why?
| | Hydroquinones | 2 | 2000 | 27 | 0.050 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2022 | 174 | 0.050 |
Why?
| | Ligands | 1 | 2022 | 569 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 702 | 0.040 |
Why?
| | Middle Aged | 5 | 2020 | 26999 | 0.040 |
Why?
| | Fibroblasts | 2 | 1994 | 839 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 140 | 0.040 |
Why?
| | Graft Survival | 1 | 2020 | 480 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2023 | 519 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2018 | 70 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2016 | 3914 | 0.040 |
Why?
| | Cell Transplantation | 1 | 1997 | 37 | 0.040 |
Why?
| | Allografts | 1 | 2018 | 127 | 0.040 |
Why?
| | Proinsulin | 1 | 1997 | 49 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2000 | 726 | 0.040 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2016 | 30 | 0.030 |
Why?
| | Mesocricetus | 2 | 1992 | 30 | 0.030 |
Why?
| | Collagen Type II | 1 | 2016 | 48 | 0.030 |
Why?
| | Interleukin-1 | 1 | 2000 | 971 | 0.030 |
Why?
| | Cell Line, Transformed | 2 | 1992 | 133 | 0.030 |
Why?
| | Genetic Therapy | 1 | 1997 | 260 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2016 | 352 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2000 | 1137 | 0.030 |
Why?
| | Female | 6 | 2023 | 59913 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2016 | 346 | 0.030 |
Why?
| | Antigens, Viral, Tumor | 1 | 1994 | 6 | 0.030 |
Why?
| | Tobacco Smoke Pollution | 1 | 1997 | 221 | 0.030 |
Why?
| | Adult | 4 | 2019 | 30718 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2016 | 602 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2022 | 12608 | 0.030 |
Why?
| | Cell Adhesion | 1 | 1994 | 433 | 0.030 |
Why?
| | Cell Communication | 1 | 1994 | 282 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2016 | 1083 | 0.030 |
Why?
| | Islets of Langerhans Transplantation | 1 | 1992 | 63 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2016 | 2000 | 0.030 |
Why?
| | Male | 5 | 2019 | 55949 | 0.030 |
Why?
| | Pregnancy | 1 | 2023 | 5548 | 0.020 |
Why?
| | Cell Separation | 1 | 1992 | 293 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 1918 | 0.020 |
Why?
| | Autoantibodies | 1 | 2019 | 1360 | 0.020 |
Why?
| | DNA | 1 | 1997 | 1356 | 0.020 |
Why?
| | Skin Tests | 1 | 2010 | 130 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 1997 | 1756 | 0.020 |
Why?
| | Glucose | 1 | 1994 | 904 | 0.020 |
Why?
| | Siblings | 1 | 2010 | 223 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4440 | 0.020 |
Why?
| | Child, Preschool | 2 | 2014 | 9133 | 0.020 |
Why?
| | Ethambutol | 1 | 1987 | 20 | 0.020 |
Why?
| | Animals | 5 | 1997 | 32102 | 0.020 |
Why?
| | Rifampin | 1 | 1987 | 68 | 0.020 |
Why?
| | Aged | 2 | 2018 | 19251 | 0.020 |
Why?
| | HLA-B15 Antigen | 1 | 2006 | 13 | 0.020 |
Why?
| | Sequence Homology | 1 | 2006 | 40 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2006 | 297 | 0.020 |
Why?
| | United States | 1 | 2020 | 12295 | 0.010 |
Why?
| | Adolescent | 2 | 2014 | 17889 | 0.010 |
Why?
| | Child | 2 | 2014 | 18488 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2578 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 621 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2114 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2790 | 0.010 |
Why?
| | Genetic Variation | 1 | 2006 | 877 | 0.010 |
Why?
| | Ganglionic Stimulants | 1 | 2000 | 10 | 0.010 |
Why?
| | Plants, Toxic | 1 | 2000 | 28 | 0.010 |
Why?
| | Smoke | 1 | 2000 | 133 | 0.010 |
Why?
| | Nicotine | 1 | 2000 | 266 | 0.010 |
Why?
| | Depression, Chemical | 1 | 1997 | 23 | 0.010 |
Why?
| | Receptors, Transferrin | 1 | 1997 | 22 | 0.010 |
Why?
| | 3T3 Cells | 1 | 1997 | 137 | 0.010 |
Why?
| | Insulin, Long-Acting | 1 | 1997 | 52 | 0.010 |
Why?
| | Cyclosporine | 1 | 1997 | 169 | 0.010 |
Why?
| | Antioxidants | 1 | 2000 | 533 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1997 | 523 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 1997 | 397 | 0.010 |
Why?
| | Iron | 1 | 1997 | 235 | 0.010 |
Why?
| | Mice, Inbred NOD | 1 | 1997 | 560 | 0.010 |
Why?
| | Young Adult | 1 | 2010 | 10470 | 0.010 |
Why?
| | Transfection | 1 | 1997 | 866 | 0.010 |
Why?
| | Cell Survival | 1 | 1997 | 1024 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 1997 | 666 | 0.010 |
Why?
| | RNA | 1 | 1997 | 819 | 0.010 |
Why?
| | Mice | 2 | 1997 | 15052 | 0.010 |
Why?
| | Liver | 1 | 1997 | 1690 | 0.010 |
Why?
| | Blood Glucose | 1 | 1997 | 1824 | 0.000 |
Why?
| | Cell Differentiation | 1 | 1992 | 1700 | 0.000 |
Why?
|
|
Aubrey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|